NICHD supports a broad range of contraceptive research, including efforts to develop male contraceptives and Multipurpose Prevention Technologies (MPTs). MPT products that prevent both pregnancy and sexually transmitted infections (STIs) would increase sexual and reproductive health options for both women and men. MPTs are composed of a combination of drugs that can target prevention of pregnancy, STIs and/or HIV, delivered using either an on-demand and event-driven or long-acting drug delivery system (DDS) with rheological/biophysical properties and product user perceptions (look, feel, effectiveness, safety and duration of action) that support user uptake (first use, subsequent use and habitual use). By combining prevention products for pregnancy and HIV or STI, the MPT may have a greater uptake and adherence than individual products. Key to the concept of MPTs is creation of DDS to support convenience of use, that not only are safe and deliver the drugs consistently but have durations of action relevant to the user needs. MPTs (contraceptive and non-contraceptive) may encompass a wide range of delivery durations and use patterns from on demand, event-driven or sustained/extended-release durations (months to years). The objective of this contract is to obtain preclinical and/or clinical (e.g., Phase 1) multipurpose prevent technologies (MPT, contraceptives with anti-infective properties: e.g., anti-HIV) related consulting services for a range of product development considerations. This includes developing contraceptives technologies with anti-infective properties against pathogens such as HIV, Bacterial Vaginosis, Chlamydia, etc. supported by NICHD’s Contraception Research Branch. These services shall provide expert consultation to NICHD staff on pre-clinical, Phase 1 clinical, ethical, policy, and regulatory issues related to NICHD’s extramural contraceptive research portfolio and other related product development related areas, as directed by NICHD staff.